Literature DB >> 26985016

Understanding mechanisms of hypertension in systemic lupus erythematosus.

Erin B Taylor1, Michael J Ryan2.   

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that predominately affects women of reproductive age. Hypertension is an important cardiovascular risk factor that is prevalent in this patient population. Despite the high incidence of hypertension in women with SLE, the pathophysiological mechanisms underlying the development of hypertension remain poorly understood. This review will focus on disease-related factors, including inflammation, autoantibodies, and sex hormones that may contribute to hypertension in patients with SLE. In addition, we will highlight studies performed by our laboratory using the female NZBWF1 (F1 hybrid of New Zealand Black and New Zealand White strains) mouse model, a spontaneous model of SLE that mimics human disease and develops hypertension and renal injury. Specifically, using female NZBWF1 mice, we have demonstrated that multiple factors contribute to the pathogenesis of hypertension, including the inflammatory cytokine, tumor necrosis factor (TNF)-α, oxidative stress, as well as B-cell hyperactivity and autoantibody production.
© The Author(s), 2016.

Entities:  

Keywords:  autoantibodies; cardiovascular disease; estrogens; hypertension; inflammation; systemic lupus erythematosus

Year:  2016        PMID: 26985016      PMCID: PMC5065379          DOI: 10.1177/1753944716637807

Source DB:  PubMed          Journal:  Ther Adv Cardiovasc Dis        ISSN: 1753-9447


  125 in total

1.  Risk factors related to hypertension in a Spanish systemic lupus erythematosus cohort.

Authors:  J M Sabio; J D Mediavilla; C Fernández-Torres; L Aliaga; J Jiménez-Alonso
Journal:  Lupus       Date:  2001       Impact factor: 2.911

Review 2.  Anti-DNA antibodies: aspects of structure and pathogenicity.

Authors:  Y J Jang; B D Stollar
Journal:  Cell Mol Life Sci       Date:  2003-02       Impact factor: 9.261

Review 3.  Estrogen receptors in immunity and autoimmunity.

Authors:  Melissa Cunningham; Gary Gilkeson
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

4.  17-β-estradiol affects BLyS serum levels and the nephritogenic autoantibody network accelerating glomerulonephritis in NZB/WF1 mice.

Authors:  N Bassi; R Luisetto; A Ghirardello; M Gatto; M Valente; M Della Barbera; L Nalotto; L Punzi; A Doria
Journal:  Lupus       Date:  2015-04       Impact factor: 2.911

Review 5.  Circulating endothelial cells and vascular injury in systemic lupus erythematosus.

Authors:  R M Clancy
Journal:  Curr Rheumatol Rep       Date:  2000-02       Impact factor: 4.592

Review 6.  The emerging role of interferon in human systemic lupus erythematosus.

Authors:  Emily C Baechler; Peter K Gregersen; Timothy W Behrens
Journal:  Curr Opin Immunol       Date:  2004-12       Impact factor: 7.486

7.  Restoration of T cell depression and suppression of blood pressure in spontaneously hypertensive rats (SHR) by thymus grafts or thymus extracts.

Authors:  D Ba; N Takeichi; T Kodama; H Kobayashi
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

Review 8.  The role of cytokines in the pathogenesis of systemic lupus erythematosus - from bench to bedside.

Authors:  Desmond Yat Hin Yap; Kar Neng Lai
Journal:  Nephrology (Carlton)       Date:  2013-04       Impact factor: 2.506

9.  Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.

Authors:  Martin Aringer; Winfried B Graninger; Günter Steiner; Josef S Smolen
Journal:  Arthritis Rheum       Date:  2004-10

10.  Potential relevance of alpha(1)-adrenergic receptor autoantibodies in refractory hypertension.

Authors:  Katrin Wenzel; Hannelore Haase; Gerd Wallukat; Wolfgang Derer; Sabine Bartel; Volker Homuth; Florian Herse; Norbert Hubner; Herbert Schulz; Marion Janczikowski; Carsten Lindschau; Christoph Schroeder; Stefan Verlohren; Ingo Morano; Dominik N Muller; Friedrich C Luft; Rainer Dietz; Ralf Dechend; Peter Karczewski
Journal:  PLoS One       Date:  2008-11-17       Impact factor: 3.240

View more
  14 in total

1.  Expansion of regulatory T cells using low-dose interleukin-2 attenuates hypertension in an experimental model of systemic lupus erythematosus.

Authors:  Erin B Taylor; Jennifer M Sasser; Kenji J Maeda; Michael J Ryan
Journal:  Am J Physiol Renal Physiol       Date:  2019-03-20

Review 2.  Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases.

Authors:  Elena Bartoloni; Alessia Alunno; Roberto Gerli
Journal:  Nat Rev Cardiol       Date:  2017-08-24       Impact factor: 32.419

Review 3.  Role of Inflammatory Diseases in Hypertension.

Authors:  E Bartoloni; A Alunno; V Valentini; F Luccioli; E Valentini; G La Paglia; O Bistoni; Roberto Gerli
Journal:  High Blood Press Cardiovasc Prev       Date:  2017-06-09

4.  Direct measurement of B-cell receptor repertoire's composition and variation in systemic lupus erythematosus.

Authors:  S Liu; X L Hou; W G Sui; Q J Lu; Y L Hu; Y Dai
Journal:  Genes Immun       Date:  2017-01-05       Impact factor: 2.676

5.  Class switching and high-affinity immunoglobulin G production by B cells is dispensable for the development of hypertension in mice.

Authors:  Yuhan Chen; Bethany L Dale; Matthew R Alexander; Liang Xiao; Mingfang Ao; Arvind K Pandey; Charles D Smart; Gwendolyn K Davis; Meena S Madhur
Journal:  Cardiovasc Res       Date:  2021-03-21       Impact factor: 10.787

Review 6.  Cardiovascular disease prevention in individuals with underlying chronic inflammatory disease.

Authors:  Brittany Weber; Katherine P Liao; Marcelo DiCarli; Ron Blankstein
Journal:  Curr Opin Cardiol       Date:  2021-09-01       Impact factor: 2.108

7.  Incidence and survival impact of pulmonary arterial hypertension among patients with systemic lupus erythematosus: a nationwide cohort study.

Authors:  Hung-An Chen; Tsai-Ching Hsu; Su-Ching Yang; Chia-Tse Weng; Chun-Hsin Wu; Chien-Yao Sun; Chun-Yu Lin
Journal:  Arthritis Res Ther       Date:  2019-03-27       Impact factor: 5.156

8.  Cyclophosphamide treatment for hypertension and renal injury in an experimental model of systemic lupus erythematosus.

Authors:  Victoria L Wolf; Erin B Taylor; Michael J Ryan
Journal:  Physiol Rep       Date:  2019-05

Review 9.  Management of cardiovascular disease in patients with systemic lupus erythematosus.

Authors:  Paramarjan Piranavan; Andras Perl
Journal:  Expert Opin Pharmacother       Date:  2020-06-08       Impact factor: 3.889

Review 10.  Contribution of Th17 cells to tissue injury in hypertension.

Authors:  David P Basile; Justine M Abais-Battad; David L Mattson
Journal:  Curr Opin Nephrol Hypertens       Date:  2021-03-01       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.